Syreeta Tilghman to Aromatase Inhibitors
This is a "connection" page, showing publications Syreeta Tilghman has written about Aromatase Inhibitors.
Connection Strength
1.989
-
Walker RR, Patel JR, Gupta A, Davidson AM, Williams CC, Payton-Stewart F, Bou? SM, Burow ME, Khupse R, Tilghman SL. Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis. Int J Mol Sci. 2022 Mar 07; 23(5).
Score: 0.857
-
Walker RR, Gallegos KM, Bratton MR, Lemieux KP, Zhang K, Wang G, Davidson AM, Tilghman SL. Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade. Anticancer Res. 2021 Feb; 41(2):583-599.
Score: 0.794
-
Patel JR, Banjara B, Ohemeng A, Davidson AM, Bou? SM, Burow ME, Tilghman SL. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1. Nutrients. 2023 Mar 28; 15(7).
Score: 0.230
-
Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O. Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):884s-8s.
Score: 0.065
-
Long BJ, Tilghman SL, Yue W, Thiantanawat A, Grigoryev DN, Brodie AM. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol. 1998 Nov; 67(4):293-304.
Score: 0.042